Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
Martin Kaiser(Royal Marsden NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Kristian M. Bowles(University of East Anglia), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Gordon Cook(University of Leeds), Christina Messiou(Institute of Cancer Research), Mark T. Drayson(Institute of Immunology), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Nicola Newnham(University of Birmingham), Anand Lokare(University Hospitals Coventry and Warwickshire NHS Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sarah Brown(University of Leeds), Katrina Walker(University of Leeds), Emma Ingleson(University of Leeds), Sadie Roberts(University of Leeds), Andrew Hall(University of Leeds), Graham Jackson(Newcastle College), Ruth M. de Tute(St James's University Hospital), Amy L. Sherborne(Institute of Cancer Research), Richard S. Houlston(Institute of Cancer Research)
Cited by 114
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605